Subcutaneous use of treprostinil in pediatric pulmonary hypertension patients: A report of three cases Pediatrik pulmoner hipertansiyon hastalarında subkutan treprostinil kullanımı: Üç olgu sunumu

KAVGACI A., KULA S., İncedere F., TOKGÖZ S., TUNAOĞLU F. S.

Turkish Journal of Thoracic and Cardiovascular Surgery, vol.31, no.1, pp.145-148, 2023 (SCI-Expanded) identifier identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 31 Issue: 1
  • Publication Date: 2023
  • Doi Number: 10.5606/tgkdc.dergisi.2023.23748
  • Journal Name: Turkish Journal of Thoracic and Cardiovascular Surgery
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, TR DİZİN (ULAKBİM)
  • Page Numbers: pp.145-148
  • Keywords: Pulmonary arterial hypertension, subcutaneous, treprostinil
  • Gazi University Affiliated: Yes

Abstract

Treprostinil was approved by the United States Food and Drug Administration for use in the treatment of pulmonary arterial hypertension in 2002. Intravenous or subcutaneous treprostinil is used in pulmonary arterial hypertension patients in the functional classes of II-IV to alleviate exercise-related symptoms, or in cases where epoprostenol treatment should be reduced due to side effects. In this article, we describe three pediatric cases of pulmonary arterial hypertension in whom subcutaneous treprostinil was used.